A Double-Blind (Incorporating an Open Label Comparator), 3-Period, Crossover Study to Determine the Pharmacokinetic Profile and Tolerability of Single Doses of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler Compared to ADVAIR® DISKUS® in Patients With Persistent Asthma 4 Through 11 Years of Age
Phase of Trial: Phase I
Latest Information Update: 14 Jun 2018
At a glance
- Drugs Fluticasone propionate (Primary) ; Salmeterol/fluticasone propionate (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Sponsors Teva Branded Pharmaceutical Products R&D
- 22 Aug 2016 Status changed from recruiting to completed.
- 13 Apr 2016 Status changed from not yet recruiting to recruiting.
- 01 Mar 2016 Planned End Date changed from 1 Aug 2016 to 1 Sep 2016, according to ClinicalTrials.gov record.